about
Multiple sclerosis. TNFRSF1A, TRAPS and multiple sclerosisAutoantibodies to MOG in a distinct subgroup of adult multiple sclerosisMonthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.Natalizumab use during the third trimester of pregnancy.GAD antibody-associated limbic encephalitis in a young woman with APECED.Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathyThe immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity.Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders.Expanding spectrum of neurologic manifestations in patients with NLRP3 low-penetrance mutations.Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75.Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid.Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol.MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis.Delayed diagnosis of extraovarian teratoma in relapsing anti-NMDA receptor encephalitis.Novel multiple sclerosis susceptibility loci implicated in epigenetic regulationContactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals.Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses.Seasonal variations of 25-OH vitamin D serum levels are associated with clinical disease activity in multiple sclerosis patients.Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.Dynamic Contrast-Enhanced Magnetic Resonance Imaging Suggests Normal Perfusion in Normal-Appearing White Matter in Multiple Sclerosis.Influence of female sex and fertile age on neuromyelitis optica spectrum disorders.Symptoms related to tumor necrosis factor receptor 1-associated periodic syndrome, multiple sclerosis, and severe rheumatoid arthritis in patients carrying the TNF receptor superfamily 1A D12E/p.Asp41Glu mutation.Genome-wide significant association with seven novel multiple sclerosis risk loci.Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies.Late-onset tumor necrosis factor receptor-associated periodic syndrome in multiple sclerosis patients carrying the TNFRSF1A R92Q mutation.Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor.Late-onset neutropenia during long-term rituximab therapy in neuromyelitis optica.Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array.TNFRSF1A and MEFV mutations in childhood onset multiple sclerosis.CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis.Multiple sclerosis-like lesions and type I interferon signature in a patient with RVCL.Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice.Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients.[Progress of therapy in patients with multiple sclerosis].Activity of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: correlations with gadolinium-enhancing lesions and ventricular volume.
P50
Q28260074-98DB1E3C-510D-4F39-A9B1-218824A408F1Q29036090-47BE0249-1F8B-43F0-B776-1A876A91717BQ30816299-39421432-A60F-4667-AE50-C9376B4E8C1DQ33415256-66A77F11-F644-48A3-BB1E-BB78DDC78CA2Q33730656-731764CA-FFF9-419E-9A18-A5E6E4F2E983Q34158293-D63210EC-FA8D-47AF-BFDE-FDF13C66DB19Q34324861-8566046D-A4C3-4E44-BA20-596B3A16A8E1Q34810293-2FB6D246-76D3-449E-9C4D-B5E37E0422A9Q35052199-B86EE3DC-030D-4727-A824-ED1FE51ECEB5Q35544312-CF8D2935-19E3-4A52-9F90-0DBEA18990FFQ35621217-1BFE95EB-7739-4E06-8D08-8D833B295352Q35638438-A1F38A03-CA7D-4ADD-B0A0-5E8B10FC4317Q35675602-6F093629-BCBC-4A76-89DE-55C2A8B1E133Q35873009-FE359E5F-82CC-4599-8A70-C567C6B2256FQ36670604-AA1EA566-25AF-4779-B8CA-55118380A24EQ36904914-9AF98C2E-5700-4EB3-8710-4D44469A93EDQ37015400-937354E4-7A53-451A-9CB7-57BAC7150327Q37056269-4417BE2C-8FA6-449B-8A3B-41683220F457Q37208572-09233A0B-78FE-450C-9DF9-D95AE971243DQ38152451-B61214B5-409A-4700-962A-7B67406FE75EQ38625492-B921AE2D-D75C-4AA7-9C86-E12CD374AEBFQ38742739-39FDCC23-BE55-442F-8223-93D57FD1C648Q38750021-274E1798-D5E0-4402-BE09-4B77AD3DEAA2Q38933803-A9030E6B-7138-4086-8E25-E2D7CE9DD54EQ39272311-8CB4BB78-F5C3-4BA9-9B65-F37C77F0B933Q40260831-5FB2B23B-2085-4BA5-9D26-828B132D0C8FQ40422665-1B0DB89C-4D45-4729-AEB9-86DEC7D7BD53Q40439689-A8C0F4B2-7D20-46F6-B3AC-E52ACEABEB8AQ40443227-E9B29844-36A2-4EF1-B8BB-37D397810FFFQ40695678-9C3CB424-519D-4472-9DE6-DE46002D15D9Q41067305-3EAC7B9D-7270-4242-967F-85343804595AQ41189386-332BAC7E-F729-4814-9726-18A81C850CE3Q41929647-5D363F45-A908-4CE9-B4BA-B33A1411A285Q42017141-6A011977-11E4-4308-A0D1-20B270711954Q42148793-82FCE3D1-0D66-4B8D-9F27-0935B0112809Q42181572-D3D4B752-FDC1-4DB9-A77D-FD3F328828F3Q42263596-FA23B7F7-9E6E-4061-B3CF-ACCCE0921B61Q42427291-0E60DF31-651B-4C4D-86E5-B5453659250FQ43103229-6FE59412-CD1B-4A8C-83CD-97345E34E39FQ44060083-A211915F-5916-4E9C-B0D5-539C9E742463
P50
name
Tania Kümpfel
@ast
Tania Kümpfel
@en
Tania Kümpfel
@es
Tania Kümpfel
@nl
type
label
Tania Kümpfel
@ast
Tania Kümpfel
@en
Tania Kümpfel
@es
Tania Kümpfel
@nl
prefLabel
Tania Kümpfel
@ast
Tania Kümpfel
@en
Tania Kümpfel
@es
Tania Kümpfel
@nl